Global Update EuFMD Exec. Committee

Transcription

1 Global Update EuFMD Exec. Committee Donald King WRLFMD Team: Valerie Mioulet, Nick Knowles, Anna Ludi, Ginette Wilsden, Bryony Armson, Pip Hamblin, Kasia Bachanek-Bankowska, Lissie Hendry, Jemma Wadsworth, Britta Wood, Barsha Thapa, Bob Statham, Abid Bin-Tarif, Ashley Gray, Emma Fishbourne, Beth Johns, Mark Henstock, Alison Morris, David Paton, Nick Lyons, Dexter Wiseman, Trish Ryder, Sarah Belgrave FMD Reference Laboratory

2 BBSRC National Virology Centre: The Plowright Building Jan-Sept 2015: Occupied new high containment laboratory Transfer of QA accreditation Houses all work with live FMD and International Reference Laboratories for FMD, BT, PPR, ASF, AHS, Capripox

3 Submissions to WRLFMD Pirbright October 2013 September 2015 (period of current LoA) Israel PAT South Korea Trinidad Chinese Taipei Hong Kong SAR A O Asia-1 SAT 1 SAT 2 FMDV GD Sequence exchange with China, Russia, India and BVI Reports for these samples can be found at:

4 Recent submissions to WRLFMD Pirbright Since last EuFMD Exec. Comm. (Belgrade, Feb 2015) Reports ( for: Afghanistan, Bahrain, Botswana, Ethiopia, Egypt, Hong Kong SAR, Kazakhstan, Laos, Mauritania, Mongolia, Oman, Pakistan, South Korea, Taiwan (Chinese Taipei), Tanzania, Thailand, Vietnam, Zimbabwe (18 countries) Results pending for: Botswana, Mozambique, Namibia, Niger, Saudi Arabia (A?), Turkey, Uganda, Zimbabwe

5 Changing epidemiological patterns O: North Africa SAT2: & Middle East Outbreaks reported to the OIE (change of epidemiological status):

6 New FMD outbreaks in Algeria: FMD outbreaks reported (initial outbreak on 2/3/2015) Disease in small ruminants foci in the west of the country? O/ME-SA/Ind-2001 confirmed by IZSLER Reported to OIE as resolved 3/5/2015 Increased threats to Morocco and Europe? also outbreaks due to O/ME-SA/Ind-2001 in Bahrain (February/March 2015)

7 Vaccine matching for O/ME-SA/Ind field isolates Vaccine strain Field Isolate O-3039 O Manisa O/TUR/5/09 LIB 1/2013 LIB 7/2013 LIB 17/2013 LIB 22/2013 NEP 13/2012 NEP 6/2012 NEP 21/2012 NEP 6/2013 NEP 18/2013 NEP 1/2014 NEP 6/2014 SAU 1/2013 SAU 4/2013 SAU 6/2013 SAU 7/2013 SAU 1/2014 SRL 1/2013 SRL 1/2014 UAE 1/2014 UAE 2/2014 ALG 1/2014 TUN 1/2014 BAR 8/2015 BAR 14/2015 borderline borderline borderline borderline borderline borderline borderline borderline

8 Vaccine Potency Trial O/ME-SA/Ind2001 Funded via EU (from EU-RL) contribution Simultaneous cattle passage required (funded from UK and Dutch National Projects) Experiments hosted by CVI-Lelystad Design agreed after discussions with FMD experts in Italy, UK, Germany and The Netherlands Adopted protocol according to European Pharmacopeia O-Manisa vaccination (6PD 50 ) with O/ALG/2014 challenge Estimated heterologous potency ~3 PD 50

9 SAT 2 Mauritania and Oman New SAT 2 samples from field outbreaks VP1 sequencing: two different genetic groups within topotype VII Mauritania 2014 Oman 2015: Cattle Genetically similar to FMD viruses from previous outbreaks in Egypt (Alx-12 sub-lineage) Mauritania 2014: Cattle Genetically most similar to FMD viruses from Nigeria OMAN 2015

10 Changing epidemiological patterns O: North Africa SAT2: & Middle East Multiple lineages East Asia Outbreaks reported to the OIE (change of epidemiological status):

11 Kinmen Island, Chinese Taipei (Taiwan)

12 Kinmen Island, Chinese Taipei (Taiwan) Cattle sampled in March 2015 at an abattoir on Kinmen Island NSP test identified a +ve reactor 2 additional NSP reactors within index case herd No clinical signs of FMD Probang sample test at AHRI was RT-PCR positive / VI negative Sequence generated serotype A (A/ASIA/Sea-97) Samples (n= 6 probang) sent to WRLFMD FMDV NVD Sera (n= 11) tested at WRLFMD by VNT and LPBE were positive for serotype O (vaccine?) and A A/GZ-YA/CHA/2013 (KJ646646) A/GZ-GY/CHA/2013 (KJ646651) A/GZ-BY/CHA/2013 (KJ646645) A/GZ-WD/CHA/2013 (KJ646648) A/GZ-XF/CHA/2013 (KJ646657) A/GZ-JC/CHA/2013 (KJ646650) A/GZ-ZB/CHA/2013 (KJ646649) A/GZ-HX/CHA/2013 (KJ646647) A/Zabaikalsky/RUS/2013 (ARRIAH) A/GDMM-CHA-2013-S (KF450794) A/KAZ/1/2013* (ARRIAH) A/KAZ/2/2013* (ARRIAH) A/MOG/3/2013 A/MOG/5/2013 A/MOG/2013 (ARRIAH) 90 A/MOG/1/2013 A/MOG/2/2013 A/MOG/4/2013 A/Amur/2/RUS/2013 (ARRIAH) A/Amur/4/RUS/2013 (ARRIAH) A/Zabaikalsky/6/RUS/2013 (ARRIAH) 95 A/Zabaikalsky/1/RUS/2014* (ARRIAH) A/Amur/RUS/2013* (ARRIAH) 83 A/Amur/3/RUS/2013 (ARRIAH) A/KM/TAW/2015* (NVRI) A/Zabaikalsky/5/RUS/2013 (ARRIAH) 94 A/Zabaikalsky/2/RUS/2014* (ARRIAH) A/MOG/11/2013 A/MOG/12/ A/MOG/13/2013 A/VIT/25/ A/VIT/26/ A/TAI/15/2012 A/TAI/3/2011 A/TAI/16/2011 A/TAI/1/ A/MAY/2/ A/TAI/10/2011 A/TAI/9/ A/TAI/3/ A/TAI/4/2012 A/MAY/4/2011 A/TAI/7/2010 A/TAI/8/2010 A/TAI/15/2011 A/TAI/13/2012 A/TAI/16/ A/VIT/15/ A/VIT/16/2012 A/VIT/17/ A/VIT/18/2012 A/VIT/19/2012 A/VIT/20/2012 A/TAI/7/2003 (HQ116312) A/TAI/2/97 (EF208778) Thai-87 Iran-96 Iran-87 Iran-99 Iran-05 A22 A15 EURO-SA AFRICA Sea-97 ASIA 0.02

13 South Korea FMD outbreaks in 2014/15 (all serotype O) July outbreaks Pigs Gyeongsangbuk-do and Gyeongsangnam-do December reported outbreaks Pigs affected West and central parts of the country Reported as resolved to OIE on 22/5/ &cloc=rss%7Cnews%7Cjoongangdaily Clinical cases in vaccinated pigs (Merial antigen)

14 Invited visit to Korea (Sept 2015) KISTOCK livestock trade show Korean Pig Producers Association Korean Association of Swine Veterinarians Meeting at QIA (national reference laboratory) Main topics of discussion 1. Reluctance to vaccinate by farmers Penalties due to tissue granulomas at injection site 2. Extent of FMD circulation in the country Control policy and NSP positive animals 3. Advice regarding future procurement of vaccines Other FMD threats to South Korea Pilot trials and vaccine effectiveness studies

15 Complete genome analysis Natural deletion of VPg1 in O/SKR/6/2014 Further investigation of the clinical disease produced by this natural deletion are needed. 3A 3B VPg1 3B VPg2 3B VPg3 3C pro Red box indicates the deleted amino acids

16 Changing epidemiological patterns O: North Africa SAT2: & Middle East Multiple lineages East Asia SAT 2: Southern Africa Outbreaks reported to the OIE (change of epidemiological status):

17 Training mission(s) Kazakhstan Kazakhstan National Reference Laboratory and Kazakhstan Veterinary Research Institute Organised by the OIE Technical assistance to support FMD-free zones in Kazakhstan: Serological tests for FMD surveillance Calibration of ELISAs for post-vaccine evaluation Molecular tests for strain identification and characterisation Exchange visit in August 2015 Training visit to Astana, Kazakhstan October 2015

18 Training Mongolia: July 2015 Request from Mongolian National Reference Laboratory Supported by the Swiss Government Troubleshooting and calibration of ELISAs for post-vaccine evaluation Practical (hands-on) training and lectures by WRLFMD staff

19 Some other missions and meetings Members of WRLFMD Team March 2105: SEACFMD Manila, Philippines April 2015: Outbreak training in Tanzania April 2015: OIE Working Group - Vaccine Banks for North Africa April 2015: West EurAsia Road Map Meeting, Kazakhstan May 2015: OIE General Session discussions with South Africa and Korea regarding vaccination June 2015: WAVLD OIE symposium June 2015: Emerging Pig Diseases Conf. July 2015: OIE Biothreat reduction symposium July 2015: IAEA Vienna FMD diagnostic training August 2015 EuFMD Training Kenya September 2015: EpiNet Group of SEACFMD

20 Vaccine Bank Recommendations (Sept. 15) High Priority Medium Priority Low Priority New vaccines (to be released shortly?) Merial (O-Panasia-2, O/SKR) MSD (O/SKR) O Manisa O PanAsia-2 (or equivalent) O BFS or Campos A24 Cruzeiro Asia 1 Shamir A Iran-05 (or A TUR 06) A22 Iraq SAT 2 Saudi Arabia (or equivalent i.e. SAT 2 Eritrea) A Eritrea SAT 2 Zimbabwe SAT 1 South Africa A Malaysia 97 (or Thai equivalent such as A/Sakolnakorn/97) A Argentina 2001 O Taiwan 97 (pig-adapted strain or Philippine equivalent) A Iran 96 A Iran 99 A Iran 87 or A Saudi Arabia 23/86 (or equivalent) A15 Bangkok related strain A87 Argentina related strain C Noville SAT 2 Kenya SAT 1 Kenya SAT 3 Zimbabwe

21 A new tool for vaccine antigen selection WRLFMD/EuFMD/SAFOSO Improved (more transparent) categorisation of different FMDV vaccine antigens Ability to respond to changing epidemiological risks Accommodates use of vaccines across different lineages For use in FMD-free settings Determines scores as a product of two components 1. Different risks and associated FMDV lineages the are specific to a particular region (Europe, NA, Aus/NZ) 2. Uses available in-vitro, in-vivo and field data to score the ability of available vaccines to protect against the different lineages Adds up the cumulative antigen score for each vaccine antigen to generate a heat map of vaccine priorities

22 Different pathways Pathway and lineage weighting Pathway Bioscore Total O-Manisa O-3039 O-TUR O-SKR O-BFS O-Campos O-TAW/98 A22 A24 A-Iran-05 A-TUR/2006 A-Eritrea A-May/97 A-Arg/2001 Asia1-Shamir SAT2-ERI SAT2-SAU SAT2-ZIM SAT1 C Cartoon overview of tool Virus lineages Risks X Vaccine coverage Lineage gaps O/ME-SA/PanAsia A/ASIA/Iran Asia O/SEA/Mya O/ME-SA/PanAsia A/ASIA/Sea-97 8 O/CATHAY 8 6 O/ME-SA/Ind SAT 2/IV and /VII) O/EA A/AFRICA O/EURO-SA A/EURO-SA C 1 9 Vaccine Priority Vaccine performance against the different FMDV lineages Agreement with vaccine companies (Merial and MSD) Data to be populated into table

23 Acknowledgements Support for the WRLFMD and research projects Collaborating FMD Reference Laboratories and field teams Partners within the OIE/FAO FMD Lab Network